Analysis shows liver stiffness and serum biomarkers do not predict fibrosis regression in chronic hepatitis B, suggesting need for better models.
Changes in the LSM and noninvasive models were not strong predictors of liver fibrosis regression after 78 weeks and 260 weeks of treatment among CHB patients. It is critical to develop a dynamic noninvasive model for assessing liver fibrosis regression (ClinicalTrials.gov identifier NCT02849132).
No takes yet. Share an insight, caveat, or question.
Jiayi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: